GeneDx (NASDAQ:WGS) Posts Earnings Results, Beats Expectations By $0.20 EPS

GeneDx (NASDAQ:WGS) issued its earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.20, FiscalAI reports. The firm had revenue of $114.44 million during the quarter, compared to analysts’ expectations of $111.01 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter last year, the company posted $0.36 earnings per share.

Here are the key takeaways from GeneDx’s conference call:

• Record testing volume and return to profitability: GeneDx processed 30,785 exome and genome tests in Q2, up 32% year over year, generated $114.4 million in revenue, and posted $0.4 million in adjusted net income. The company reaffirmed full-year revenue guidance of $475 million–$490 million and expects to remain profitable for 2026.
• Coverage expansion creates a potential reimbursement tailwind: Commercial genome coverage increased from 47% to 87% of covered lives, driven largely by Carelon, while 39 states now cover exome or genome testing through Medicaid. Management expects the revenue impact to begin emerging in Q4 2026 and become more significant in 2027 as coverage translates into claims payments.
• Revenue cycle management is the primary growth opportunity but remains early: The outpatient genome collection rate was approximately 32%, with exome rates described as comparable, versus management’s long-term target of roughly 70%. Payer-specific workflows, improved prior authorization and denial management, and technology investments are being implemented, but collection rates are expected to remain roughly flat in Q3.
• Demand is broadening beyond GeneDx’s core markets: The company maintained about 80% share among geneticists and reached roughly 50% among pediatric neurologists, while General Pediatrics and prenatal testing showed early growth. New sales representatives, corporate pediatric accounts, and the planned “one-minute” ordering tool are expected to support further adoption.
• Liquidity and operating efficiency improved: GeneDx completed its planned $25 million in annual cost reductions, expanded its debt facility by $50 million, and received a strategic equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million. Management also cited gross-margin improvement to 70%, additional AI-driven productivity opportunities, and a return to cash-flow generation expected in Q4.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $67.86 on Tuesday. The company has a market capitalization of $2.01 billion, a PE ratio of -25.32 and a beta of 1.92. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The company’s fifty day moving average price is $61.08 and its 200 day moving average price is $69.30. GeneDx has a 1 year low of $32.21 and a 1 year high of $170.87.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Quarterly results beat estimates: GeneDx reported adjusted EPS of $0.01, above the consensus estimate of a $0.19 loss, while revenue increased 11.4% year over year to $114.4 million, ahead of expectations. GeneDx quarterly earnings report
• Positive Sentiment: Full-year revenue guidance reaffirmed: Management maintained its 2026 revenue forecast of $475 million to $490 million, broadly in line with the $477.1 million analyst consensus. The company expects a meaningful improvement in collection rates beginning in the fourth quarter, which could support future revenue quality and cash generation. GeneDx reaffirms 2026 revenue guidance
• Positive Sentiment: Gross profit increased: Gross profit rose approximately 10% to $78.2 million, indicating that GeneDx continues to expand its top line despite a challenging profitability environment. GeneDx second-quarter financial results
• Neutral Sentiment: Investor positioning is mixed: Recent institutional filings showed both sizable additions and reductions in WGS positions. Reported insider activity was also mixed, with large purchases by certain investors alongside sales by company executives, offering no clear signal about near-term sentiment.
• Negative Sentiment: Profitability and cash flow remain weak: GeneDx posted a $17.5 million operating loss, a $17.7 million net loss, and $29 million in operating cash outflow. Losses worsened from the prior year, while cash stood at $60.3 million and total liabilities reached $237.3 million. GeneDx Q2 losses and cash flow report
• Negative Sentiment: Securities litigation adds risk: Several law firms publicized a class-action lawsuit alleging securities-law violations related to purchases made between April 16, 2025, and May 4, 2026. The allegations are not proven, but the litigation could create financial, reputational, and management risks. GeneDx securities class action announcement

Insiders Place Their Bets

In other news, Director Keith A. Meister acquired 533,758 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the transaction, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Casdin Capital, Llc bought 185,000 shares of the stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the purchase, the director owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This represents a 5.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GeneDx

A number of large investors have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after purchasing an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares during the period. NewEdge Advisors LLC lifted its position in shares of GeneDx by 270,700.0% during the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after buying an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of GeneDx by 67.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after buying an additional 11,375 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in shares of GeneDx during the 2nd quarter valued at approximately $249,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on WGS shares. BTIG Research cut their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Guggenheim restated a “buy” rating and issued a $74.00 target price (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Finally, Zacks Research raised GeneDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.